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Abstract
Background: Accurate diagnosis is a fundamental aspect of appropriate healthcare. However, clinicians need
guidance when implementing diagnostic tests given the number of tests available and resource constraints in
healthcare. Practitioners of health often feel compelled to implement recommendations in guidelines, including
recommendations about the use of diagnostic tests. However, the understanding about diagnostic tests by
guideline panels and the methodology for developing recommendations is far from completely explored.
Therefore, we evaluated the factors that guideline developers and users need to consider for the development of
implementable recommendations about diagnostic tests.
Methods: Using a critical analysis of the process, we present the results of a case study using the Grading of
Recommendations Applicability, Development and Evaluation (GRADE) approach to develop a clinical practice
guideline for the diagnosis of Cow Milk Allergy with the World Allergy Organization.
Results: To ensure that guideline panels can develop informed recommendations about diagnostic tests, it
appears that more emphasis needs to be placed on group processes, including question formulation, defining
patient-important outcomes for diagnostic tests, and summarizing evidence. Explicit consideration of concepts of
diagnosis from evidence-based medicine, such as pre-test probability and treatment threshold, is required to
facilitate the work of a guideline panel and to formulate implementable recommendations.
Discussion: This case study provides useful guidance for guideline developers and clinicians about what they
ought to demand from clinical practice guidelines to facilitate implementation and strengthen confidence in
recommendations about diagnostic tests. Applying a structured framework like the GRADE approach with its
requirement for transparency in the description of the evidence and factors that influence recommendations
facilitates laying out the process and decision factors that are required for the development, interpretation, and
implementation of recommendations about diagnostic tests.
Background
High quality clinical practice guidelines that provide
implementable recommendations are the ideal tool to
improve patient outcomes in healthcare. Guidelines
must, therefore, provide transparent and explicit recom-
mendations accompanied by implementation aids. For
example, recommendations about diagnostic tests
should consider the downstream consequences of such
tests. That is, accurate diagnosis is a prerequisite for
successful therapy but an accurate diagnosis should also
not be seen in isolation. Establishing a diagnosis does
not provide information about whether a patient or a
group of patients benefits from the diagnosis. Such ben-
efit should be measured in patient-important outcomes
that can include disease-related outcomes (e.g., mortality
reduction), psychological consequences of testing as well
as resource utilization outcomes. Recommendations
about diagnostic tests should consider whether these
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if this net benefit may be worth the associated resources.
However, diagnostic test research rarely focuses on
patient important outcomes [1]. Moreover, synthesizing
evidence on diagnostic tests is particularly challenging
because statistical methods used to aggregate diagnostic
accuracy data are conceptually complex, leading to diffi-
culties with the interpretation of results [2]. Despite
these challenges, guideline developers make recommen-
dations about the use of diagnostic tests. We believe
they all too frequently do so without considering the
consequences of applying diagnostic tests in terms of
patient important outcomes [3]. In part this may be due
to the lack of appropriate guidance for developing
recommendations about diagnostic test or strategies.
The consequences of failing to acknowledge all rele-
vant aspects in developing recommendations can be
severe. For example, to develop a recommendation
about the use of a diagnostic test, one requires either
evidence directly comparing alternative diagnostic and
management strategies focusing on patient important
outcomes, or one must make assumptions about the
prevalence, diagnostic test accuracy, efficacy of interven-
tions, and about the prognosis of patients. In prior work
of the GRADE working group, we laid out the principles
and challenges related to making recommendations
about diagnostic tests, but examples for applying
GRADE or other explicit and transparent frameworks in
these situations are rare [4].
Despite the lack of applying transparent frameworks in
the development of recommendations about diagnostic
tests, it is likely that healthcare practitioners remain
unaware of these limitations and implement guideline
recommendations that lack transparency about the
assumptions underlying the recommendations, including
recommendations about the use of diagnostic tests.
Thus, the guideline enterprise requires methods for
engaging developers of recommendations in a way that
they better understand the consequences of performing
diagnostic tests to facilitate implementation of recom-
mendations. These methods include guidance on how to
present evidence to guideline developers and healthcare
practitioners, moving from evidence to recommenda-
tions and then formulating recommendations that facili-
tate implementation.
Therefore, we describe challenges and solutions
related to developing recommendations about diagnostic
tests with guideline panels. Our case study is based on
using the GRADE approach for a guideline with the
World Allergy Organization (WAO) [5] in the clinical
area of cow’s milk allergy (CMA) that affects 1.9% to
4.9% of infants [6-11]. In this article, we address consid-
erations about specifying patient-important outcomes
and summarizing evidence for guideline panels in a
comprehensive and structured manner. Furthermore, we
describe the group and consensus processes that this
guideline panel used to ensure transparent and evi-
dence-based recommendations.
This approach can serve as guidance for panels
wishing to implement the GRADE approach, a metho-
dology that has been adopted by over 50 organizations
[12], or similar approaches to develop recommendations
about diagnostic tests. It should also raise awareness of
what guideline users ought to demand from diagnostic
recommendations to facilitate the interpretation and
strengthen confidence in the recommendations.
Methods
General methods
We conducted a case study based on written records,
meeting minutes, and critical analysis of the process
used to develop the WAO CMA guidelines. Three of
the contributors to this article (HJS, JLB and JK) are
members of the GRADE working group and have, to a
varying degree, contributed to the development of the
GRADE approach.
Panel selection and composition
The panel for this guideline included 22 international
members including allergists, paediatricians, gastroenter-
ologists, dermatologists, family physicians, epidemiolo-
gists, guideline developers, allergists, food chemists, and
representatives of patient organizations. The evidence
synthesis and development of clinical recommendations
was led by two methodologists (HJS and JLB), who had
extensive experience in applying the GRADE approach.
Conflict of interest
Prior to meeting, panel members were asked to com-
plete written conflict of interest declarations, as recom-
mended by the World Health Organization [13] and
American Thoracic Society [14]. The panel agreed that
members would recuse themselves or be excused by the
chairs from discussion and voting on particular recom-
mendations, if necessary.
Group process
During the guideline development, a core group met
regularly to guide the evidence synthesis. Whenever
input from the entire panel was required initially, we
solicited it via email and teleconference calls ensuring
an economic and streamlined process. A face-to-face
meeting of all panel members was held in December
2009 to review the systematically compiled evidence,
discuss the recommendations, and agree on their word-
ing and strength. Recommendations that required addi-
tional clarification and discussion were finalized during
a follow-up conference call.
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method prior to the meeting (emailed questions seeking
independent decisions with a formal and explicit
method of aggregation of responses and feedback) and a
structured discussion method during the meeting [15].
This latter method was particularly useful in achieving
basic understanding about the complex methodological
issues in developing diagnostic recommendations and
for building consensus on recommendations. Figure 1
describes the overall process.
Formulating questions and deciding on the importance of
outcomes
It is not unusual for panels to spend one or more meet-
ings on deliberating about what should be covered in a
guideline, including developing the healthcare questions
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Figure 1 General process followed for developing clinical practice guideline on diagnostic tests.
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appropriate clinical questions using the PICO or another
structured format [16]. This step leads to focussed clini-
cal questions pertaining to a defined population (P) for
whom the diagnostic strategy or intervention (I) is being
considered in relation to a comparison strategy (C)
according to defined patient outcomes (O).
The CMA panel determined that the population of
interest would be patients–adults and children–sus-
pected of IgE-mediated CMA (i.e.,t h o s ei nw h o mt h e
diagnosis is uncertain). In search for a reference stan-
dard, the panel agreed that a blinded oral food challenge
(OFC) would be considered a proper reference test
(gold standard) in the diagnosis of CMA, against which
all test should be evaluated.
An index test (i.e., the test of interest or a ‘new’ test)
can play one of three roles in the existing diagnostic
pathway: act as a triage (to minimize use of invasive or
expensive tests), replace a current test (to eliminate tests
with worse test performance compared to a current test,
greater burden, invasiveness, or cost), or add-on (to
enhance accuracy of a diagnosis beyond current test)
[17]. During the question-generation phase, panel mem-
bers indicated that they were interested in the index
tests as a replacement for the reference standard due to
the risks, resource utilization, and burdens associated
with performing an OFC.
The main challenge in developing recommendations
for diagnostic questions is for panels to understand the
implications of the diagnostic test and the quantitative
information that diagnostic test accuracy data can pro-
vide [4]. GRADE, when making recommendations for
diagnosis, provides a structured framework that consid-
ers the following outcomes: the patient-important con-
sequences of being classified as true positive (TP), true
negative (TN), false positive (FP), or false negative (FN);
consequences of inconclusive results; complications of a
new test and a reference standard; and resource use
(cost). For example, nearly every test inevitably leads to
both correctly classified patients (that can be further
separated into TP and TN) and incorrectly classified
patients (FP and FN). Correct classification is usually
associated with benefits or a reduction in adverse out-
comes, while incorrect classification is associated with
worse consequences (harms), including failure to treat
and potentially reduce burden of disease. A guideline
panel needs to evaluate whether the benefits of a correct
classification (TP and TN) outweigh the potential harms
of an incorrect classification (FP and FN). However, the
benefits and harms follow from subsequent action and
are determined by probabilities of outcome occurrence
and the importance of these outcomes to patients (e.g.,
mortality, morbidity, symptoms, et al.). If the benefits of
being correctly classified by the test (as TP or TN) are
sufficiently greater than harms associated with being
incorrectly classified (as FP or FN), the guideline panel
may be inclined to accept lower accuracy of a diagnostic
test when recommending its use.
For these recommendations, the specific consequences
(i.e., what outcomes important to these patients usually
happen as a result of subsequent management or lack
thereof; these are based on the assumptions about the
efficacy of subsequent treatment) for patients of being
classified as TP, TN, FP, and FN were first suggested by
two clinicians experienced in managing patients with
CMA (AF and LT). The patient-important consequences
were subsequently refined explicitly by the guideline
panel using the Delphi method (see Table 1) and were
used to objectively weigh considerations when making
recommendations. These clinical implications of correct
diagnosis and misclassification (based on assumptions of
efficacy of interventions) were provided to panel mem-
bers who weighed these considerations in making
recommendations and judging the importance of
outcomes.
Guideline panel members rated the relative impor-
tance of all outcomes, given their associated conse-
quences, on a scale from one (informative but not
important for decision making) to nine (critical for deci-
sion making) a priori (without having seen the summary
of the evidence).
Identifying distinct subgroups of patients at different risk
for target condition (pre-test probability)
In formulating a diagnosis, clinicians consider a list of
possible target conditions and estimate the probability
associated with each of them (i.e., pre-test probability).
Depending on this probability, a diagnostic test can be
used with an intention to either ‘rule in’ or to ‘rule out’
a target condition. However, test accuracy and potential
complications of performing it may be such that the test
will be useful for one of the two purposes, but not for
the other. Thus, in making recommendations about the
use of diagnostic tests, one needs to consider groups of
patients with different initial (pre-test) probabilities of
the target condition.
For the CMA guidelines, the panel decided to make
recommendations for patients with low pre-test prob-
ability of CMA (e.g., patients with nonspecific gastroin-
testinal symptoms), those with moderate pre-test
probability (i.e., average prevalence of CMA in all stu-
dies included in our systematic review), and those with
a high pre-test probability (e.g., patients with history of
anaphylaxis likely to be caused by cow’s milk).
To generate approximate values of pre-test probabil-
ities (high, average, low), we abstracted the prevalence
of CMA in comparable populations identified in the stu-
dies in our systematic reviews that informed the
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was obtained from populations of patients suspected of
CMA with a history of anaphylaxis. The percentage of
this high-risk population who actually then were diag-
nosed with CMA (as verified by the reference standard)
was used as the estimate for high pre-test probability.
The estimate for low pre-test probability was obtained
from the prevalence of CMA in patients suspected of
the condition with nonspecific GI symptoms. A third
category–an average pre-test probability–was estimated
based on the average prevalence of CMA in all studies
included in our systematic review. To facilitate under-
standing and implementation of recommendations, we
provided examples of common clinical presentations
that clinicians could use to estimate if the individual
patient is at high, average, or low initial risk of CMA
when corresponding with panel members and for guide-
line users.
Using this approach, the high pre-test probability was
estimated to be approximately 80%, low pre-test prob-
ability was estimated to be approximately 10%, and aver-
age pre-test probability was estimated to be
approximately 40%. These values, in combination with
diagnostic accuracy from the systematic review, were
used to calculate the number of patients per 1,000 that
would be categorized to TP, TN, FP, and FN for each
index test depending on pre-test probability.
Test and treatment threshold work-up
Guideline panel members making recommendations
about the use of diagnostic tests must understand that
with new information provided by a diagnostic test, the
probability of the target condition can increase or
decrease. A useful diagnostic test can increase the prob-
ability of the target condition across a certain threshold
where the physician is confident to start treatment (i.e.,
treatment threshold). Alternatively, a useful diagnostic
test can decrease the probability of the target condition
below a certain threshold where the physician is confi-
dent to stop testing and rule out the disease (i.e., testing
threshold). In other words, diagnostic tests that are of
value to clinicians will sufficiently reduce uncertainty
about the target condition to rule it in or rule it out.
We solicited the panel members’ treatment and testing
thresholds for CMA to gauge the level of uncertainty
that clinicians are willing to tolerate in ruling CMA in
or out while considering the potential consequences.
This information would impact the test accuracy
Table 1 Example of the patient-important consequences of being classified into TP, TN, FP, and FN categories
Question 1: Should skin prick tests be used for the diagnosis of IgE-mediated CMA in patients suspected of CMA?
Population Patients suspected of cow’s milk allergy (CMA)
Intervention: Skin prick test (SPT)
Comparison Oral food challenge (OFC)
Outcomes
TP The child will undergo OFC, which will turn out positive with risk of anaphylaxis, albeit in controlled environment; burden
on time and anxiety for family; exclusion of milk and use of special formulae. Some children with high pre-test probability
of disease and/or at high risk of anaphylactic shock during the challenge will not undergo challenge test and be treated
with the same consequences of treatment as those who underwent food challenge.
TN The child will receive cow’s milk at home with no reaction, no exclusion of milk, no burden on family time and decreased
use of resources (no challenge test, no formulae); anxiety in the child and family may depend on the family; looking for
other explanation of the symptoms.
FP The patient will undergo an OFC, which will be negative; unnecessary burden on time and anxiety in a family; unnecessary
time and resources spent on oral challenge. Some children with high pre-test probability of CMA would not undergo
challenge test and would be unnecessarily treated with elimination diet and formula that may led to nutritional deficits (e.
g., failure to thrive, rickets, Vit D or calcium deficiency); also stress for the family and unnecessary carrying epinephrine self
injector which may be costly as well as delayed diagnosis of the real cause of symptoms.
FN The child will be allowed home and will have an allergic reaction (possibly anaphylactic) to cow’s milk at home; high
parental anxiety and reluctance to introduce future foods; may lead to multiple exclusion diet. The real cause of symptoms
(i.e., CMA) will be missed leading to unnecessary investigations and treatments.
Inconclusive results Either negative positive control or positive negative control: the child would repeat SPT which may be distressing for the
child and parent; time spent by a nurse and a repeat clinic appointment would have resource implications; alternatively,
child would have sIgE measured or undergo food challenge
Complications of a
test
SPT can cause discomfort or exacerbation of eczema that can cause distress and parental anxiety; food challenge may
cause anaphylaxis and exacerbation of other symptoms.
Resource utilization
(cost)
SPT adds extra time to clinic appointment however; OFC has much greater resource implications
TP - true positive (being correctly classified as having CMA), TN - true negative (being correctly classified as not having CMA), FP - false positive (being incorrectly
classified as having CMA), FN - false negative (being incorrectly classified as not having CMA); these outcomes are always determined in comparison with a
reference standard (i.e., food challenge test with cow’s milk)
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moving the uncertainty above the treatment threshold
or below the testing threshold. We asked panel mem-
bers to estimate treatment and testing thresholds speci-
fying a clinical setting based on history, clinical
presentation, and results of index tests alone (i.e.,w i t h -
out performing a reference test, the OFC). In detail, we
applied the following process. Together with the exer-
cise to determine the importance of outcomes, we
invited panel members by email to participate in an
‘exercise to attempt to estimate the thresholds at which
a clinician stops testing for CMA and either starts treat-
ment (CMA very probable) or informs the patient/par-
ents that CMA is not responsible for the symptoms
(CMA very improbable) using four different scenarios
(Additional file 1: Appendix 1 includes the detailed exer-
cise).’ We informed them that we acknowledge that
these thresholds we asked to estimate are subjective and
depend on one’s values and preferences. We also
acknowledged that the four scenarios we presented were
a simplification of real life situations but that this may
be an acceptable trade off between comprehensiveness
and simplicity. Following a detailed description of con-
cepts about test and treatment thresholds, contextualiza-
tion for CMA, provision of probabilities for outcomes
and cost estimates, we asked participants to determine
their test and treatment thresholds for four scenarios
that were described in detail (see Additional file 1:
Appendix 1). We utilized the results of this survey to
explore where the thresholds for test recommendations
are located along the probabilities of 0 to 100%.
Preparation of evidence profiles
For each question, we prepared one or more evidence pro-
files summarising the information about the relevant out-
comes. Evidence profiles present a concise summary of
estimated effects and an assessment of the quality of sup-
porting evidence to support informed decision making by
the panel members. Evidence profiles should ideally be
based on a systematic review. Because we did not identify
any existing systematic review of the use of tests for the
diagnosis of CMA, we performed systematic reviews. We
searched MEDLINE, EMBASE, and the Cochrane Library
(including Cochrane Central Register of Controlled Trials,
DARE, NHS EED) for relevant studies. Studies published
up to September 2009 were included. Using the results
from the systematic review, we estimated the pooled accu-
racy of each test. This served as an estimate for the num-
ber of patients that would be classified into TP, TN, FP,
and FN per 1,000 patients tested. To assess the quality of
available evidence, we used the categories described by
GRADE [4] and the QUADAS tool [18] relating to the
risk of bias, directness of the evidence, consistency and
precision of the results, and the likelihood of the
publication bias. Based on the different initial probabilities
of CMA and the estimated accuracy of each test being
evaluated, we calculated the proportion of patients who
would be classified as TP, TN, FP, and FN per 1,000
patients tested (see Table 2). Accuracy of the tests was
estimated based on a meta-analysis of the review results.
Table 3 shows the evidence profile prepared for one of the
questions posed in the guidelines.
Results
Descriptive summaries of evidence providing the inter-
pretation of numerical results accompanied evidence
profiles. These summaries explicitly stated the results of
the literature searches, provided additional information
about the included studies, enrolled patients, and tests
that had been used. They also described the anticipated
benefits and downsides of using an index test relative to
a reference standard, additional information that might
be relevant for clinical use, and suggested final conclu-
sions about the use of the new test.
During the full panel meeting, members reviewed the evi-
dence summaries, draft guidelines, discussed recommenda-
tions, and revised the recommendations if necessary.
Consensus was reached on all recommendations and their
strength considering the quality of supporting evidence, the
balance of desirable and undesirable consequences of using
a new test, cost, and patients’ values and preferences. No
recommendation required voting. The test and treatment
threshold workup yielded variable results from guideline
panel. Some panel members indicated that they were not
willing to accept any residual uncertainty about the pre-
sence of CMA. This aversion to any uncertainty is evi-
denced by providing high treatment thresholds when only
the index tests were used. These high treatment thresholds
identified a type of clinician who would always perform
reference test (OFC). As a consequence, recommendations
were made expressing that for settings where OFC would
always be performed, index tests would be redundant given
their limited accuracy and should not be used.
To increase the transparency and interpretation of
recommendations, values, and preferences that panel
Table 2 Example calculation for determining number of
patients classified as TP/TN/FP/FN per 1,000 based on
pre-test probability of 20% (based on population with
20% prevalence of CMA in target population)
Reference standard
Disease present Disease absent
New
Test
Positive TP = sensitivity ×
200
FP = (1 - specificity)
× 800
Negative FN = (1 - sensitivity)
× 200
TN = specificity ×
800
Prevalence: 20% 200 800 1000
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balance of desirable and undesirable consequences of
using a new test were explicitly stated with each recom-
mendation. Any additional information that the guide-
line panel thought might improve the understanding
and implementation of the recommendation are pro-
vided in the remarks section [5].
Following the GRADE approach, we classified recom-
mendations as either strong or conditional (also known
as ‘weak’). In total, 15 recommendations about the use
of diagnostic tests were made.
Discussion
Strengths of this approach include consideration of
the unique challenges in making recommendations
for diagnostic tests. Despite the reliance on
modelling assumptions for treatment efficacy, we
looked beyond test accuracy to explicitly outline the
risks and benefits for patients being classified as TP,
T N ,F P ,o rF N ,a sp e rt h eG R A D Ea p p r o a c h ,a n d
were able to engage a panel with a limited experience
in the development of guidelines about diagnostic
tests in this process [4]. These considerations are
otherwise left to the treating clinician. Based on this
exercise and the challenges with understanding diag-
nostic test accuracy data, additional support is
required for those making and using recommenda-
tions about diagnostic tests. We were able to provide
an understanding of the pre-test probability and clin-
icians’ testing/treatment thresholds that allowed the
guideline to provide evidence-based recommenda-
tions for clinical practice.
Table 3 Example of evidence profile generated based on systematic review conducted for these guidelines
Question 1, Profile 1: Should skin prick tests be used for the diagnosis of IgE-mediated CMA in patients suspected of CMA? Cut-off ≥3
mm | All populations
Outcome No. of
studies
Study
design
Factors that may decrease quality of evidence Final
quality
Effect per
1000
1
Importance
Limitations Indirectness Inconsistency Imprecision Reporting
bias
True positives
(patients with
CMA)
23
studies
(2302
patients)
Consecutive
or non-
consecutive
series
Serious
2 None Serious
3 None Unlikely ⊕⊕OO
low
Prev 80%:
536 Prev
40%: 268
Prev 10%:
67
CRITICAL
True negatives
(patients
without CMA)
23
studies
(2302
patients)
Consecutive
or non-
consecutive
series
Serious
2 None Serious
3 None Unlikely ⊕⊕OO
low
Prev 80%:
108 Prev
40%: 324
Prev 10%:
486
CRITICAL
False positives
(patients
incorrectly
classified as
having CMA)
23
studies
(2302
patients)
Consecutive
or non-
consecutive
series
Serious
2 Serious
4 Serious
3 None Unlikely ⊕OOO
very
low
Prev 80%:
92 Prev
40%: 276
Prev 10%:
414
CRITICAL
False
negatives
(patients
incorrectly
classified as not
having CMA)
23
studies
(2302
patients)
Consecutive
or non-
consecutive
series
Serious
2 None Serious
3 None Unlikely ⊕⊕OO
low
Prev 80%:
264 Prev
40%: 132
Prev 10%:
33
CRITICAL
Inconclusive
5 1 study
(310
patients)
Non-
consecutive
series
- - - - - - - IMPORTANT
Complications Not
reported
- - - - - - - - NOT
IMPORTANT
Cost Not
reported
- - - - - - - - NOT
IMPORTANT
Footnotes 1 to 5 provide detailed rationale underlying ratings.
1Based on combined sensitivity of 67% (95% CI: 64 to 70) and specificity of 74% (95% CI: 72 to 77)
2Most studies enrolled highly selected patients with atopic eczema or gastrointestinal symptoms, no study reported if an index test or a reference standard were
interpreted without knowledge of the results of the other test, but it is very likely that those interpreting results of one test knew the results of the other; all
except for one study that reported withdrawals did not explain why patients were withdrawn.
3Estimates of sensitivity ranged from 10% to 100%, and specificity from 14% to 100%; we could not explain it by quality of the studies, tests used or included
population
4There is uncertainty about the consequences for these patients; in some a diagnosis of other potentially serious condition may be delayed
5One study in children <12 month of age reported 8% inconclusive challenge tests but did not report number of inconclusive skin prick test
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include an emphasis on concepts related to diagnosis in
evidence-based medicine. Panel members had expressed
that interpretation of diagnostic accuracy from sensitiv-
ity and specificity was cognitively challenging. When we
translated these values into number of patients who
would be classified as TP, TN, FP, and FN per 1,000
patients tested combined with explicit judgments about
the burdens associated with being misclassified, panel
members were able to more easily grasp the clinical
implications of diagnostic tests under review.
This underscores the importance of presenting evi-
dence for guideline development in standardized format
that minimizes cognitive biases and emphasizes patient
important outcomes. Our findings are consistent with
guideline development literature that suggests that panel
members may not be familiar with the methods and
processes that are used in developing evidence-based
recommendations, especially with a multidisciplinary
group of diverse backgrounds [19]. Thus, training and
support, whether formal or informal, is key to ensuring
understanding and facilitate active participation.
The translation from sensitivity and specificity to clinical
implications of the diagnostic tests in the form of number
of patients classified as TP, TN, FP, and FN per 1,000
tested was possible because of our pre-test probability
workup. Distinguishing between high, average, and low
pre-test probabilities also allows clinicians to categorize
the spectrum of patients in utilizing the guideline. In addi-
tion, these subgroups allow for consideration of particular
benefits and risks offered by a new (index) test unique to
the subgroup (e.g., lower accuracy of index tests may be
acceptable for patients with high pre-test probability when
weighed against potential for adverse effects with a refer-
ence standard, such as anaphylaxis with OFC).
Soliciting treatment and testing threshold from panel
members also had significant implications on the
recommendations. The variability in results highlighted
the differences among panel members with regards to
the level of uncertainty that they were willing to accept
in diagnosing CMA. It revealed a group of clinicians
who would always perform the reference standard as
they would not tolerate the uncertainty left by other
tests, regardless of complications or risks associated
with OFC. Thus, recommendations offered guidance to
this type of clinicians in advising against the use of
index tests combined with OFC as they would be redun-
dant given their limited sensitivity and specificity.
Conclusion
We describe the application of the GRADE approach to
the development of diagnostic recommendations. This
case study provides useful guidance for guideline develo-
pers and clinicians about what they ought to demand from
clinical practice guidelines to facilitate implementation and
strengthen confidence in recommendations about diag-
nostic tests. The particular challenges of making diagnos-
tic recommendations were met by developing evidence
profiles explicitly defining the patient important outcomes
associated with being classified as TP, TN, FP, and FN in
addition to providing sensitivity and specificity of diagnos-
tic tests that would determine the number of patients that
would fall into each group. Furthermore, there was an
emphasis on diagnosis concepts in evidence-based medi-
cine, such as a consideration of pre-test probability and
test/treatment thresholds. Throughout the guideline, a
structured multidisciplinary panel process ensured the
methodological soundness and clinical relevance of
recommendations. In summary, applying a structured fra-
mework like the GRADE approach with its requirement
for transparency in the description of the evidence and
factors that influence recommendations facilitates laying
out the process and decision factors that are required for
the development, interpretation, and implementation of
recommendations about diagnostic tests.
Additional material
Additional file 1: Appendix 1. Determining test and treatment
thresholds.
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